Elin S Gray

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6517408/publications.pdf

Version: 2024-02-01

117 papers	6,325 citations	70961 41 h-index	71532 76 g-index
120 all docs	120 docs citations	120 times ranked	6578 citing authors

#	Article	IF	Citations
1	The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4 ⁺ T Cell Decline and High Viral Load during Acute Infection. Journal of Virology, 2011, 85, 4828-4840.	1.5	441
2	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. Journal of Virology, 2011, 85, 9998-10009.	1.5	393
3	Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C. Journal of Virology, 2008, 82, 11651-11668.	1.5	337
4	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 2015, 6, 42008-42018.	0.8	278
5	Evolution of an HIV glycanâ€“dependent broadly neutralizing antibody epitope through immune escape. Nature Medicine, 2012, 18, 1688-1692.	15.2	273
6	Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection. Journal of Virology, 2007, 81, 6187-6196.	1.5	262
7	Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection. PLoS Pathogens, 2009, 5, e1000598.	2.1	213
8	Autoantibody Production in Cancerâ€”The Humoral Immune Response toward Autologous Antigens in Cancer Patients. Autoimmunity Reviews, 2016, 15, 477-483.	2.5	196
9	Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. PLoS Pathogens, 2013, 9, e1003738.	2.1	190
10	Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors. Journal of Virology, 2009, 83, 8925-8937.	1.5	170
11	Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals. Journal of Virology, 2011, 85, 11502-11519.	1.5	168
12	Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop. Journal of Virology, 2011, 85, 3128-3141.	1.5	151
13	The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection. Journal of Virology, 2008, 82, 1860-1869.	1.5	142
14	Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting. PLoS ONE, 2011, 6, e23532.	1.1	137
15	The Development of CD4 Binding Site Antibodies during HIV-1 Infection. Journal of Virology, 2012, 86, 7588-7595.	1.5	123
16	Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?. Cancer Letters, 2020, 468, 59-71.	3.2	113
17	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 2017, 404, 62-69.	3.2	98
18	Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology, 2010, 402, 187-196.	1.1	95

#	Article	IF	Citations
19	Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clinical Biochemistry, 2015, 48, 999-1002.	0.8	95
20	Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region. Journal of Virology, 2009, 83, 11265-11274.	1.5	93
21	High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology, 2009, 387, 414-426.	1.1	86
22	Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nature Communications, 2020, 11, 2408.	5.8	86
23	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer, 2018, 18, 726.	1.1	77
24	Insensitivity of Paediatric HIV-1 Subtype C Viruses to Broadly Neutralising Monoclonal Antibodies Raised against Subtype B. PLoS Medicine, 2006, 3, e255.	3.9	72
25	Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. Journal of Investigative Dermatology, 2015, 135, 2040-2048.	0.3	66
26	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 2015, 18, 354-362.	5.1	66
27	Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies. Journal of Virology, 2013, 87, 4882-4894.	1.5	65
28	Exercise-induced myokines and their effect on prostate cancer. Nature Reviews Urology, 2021, 18, 519-542.	1.9	62
29	Specificity of the autologous neutralizing antibody response. Current Opinion in HIV and AIDS, 2009, 4, 358-363.	1.5	59
30	Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual. Journal of Virology, 2011, 85, 7719-7729.	1.5	54
31	PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. Oncologist, 2020, 25, e520-e527.	1.9	54
32	Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. Journal of Translational Medicine, 2012, 10, 192.	1.8	52
33	The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4+ cells. Virology, 2012, 423, 175-186.	1.1	50
34	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2020, 26, 4064-4071.	3.2	50
35	Binding of the Mannose-Specific Lectin, Griffithsin, to HIV-1 gp120 Exposes the CD4-Binding Site. Journal of Virology, 2011, 85, 9039-9050.	1.5	49
36	Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer, 2014, 14, 423.	1.1	48

#	Article	IF	Citations
37	Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology, 2007, 368, 172-181.	1.1	45
38	Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. Oncotarget, 2017, 8, 67355-67368.	0.8	45
39	Locusâ€specific concordance of genomic alterations between tissue and plasma circulating tumor <scp>DNA</scp> in metastatic melanoma. Molecular Oncology, 2019, 13, 171-184.	2.1	44
40	Sensitive droplet digital PCR method for detection ofTERTpromoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget, 2017, 8, 78890-78900.	0.8	44
41	N-Linked Glycan Modifications in gp120 of Human Immunodeficiency Virus Type 1 Subtype C Render Partial Sensitivity to 2G12 Antibody Neutralization. Journal of Virology, 2007, 81, 10769-10776.	1.5	42
42	Heat stress: A risk factor for skin carcinogenesis. Cancer Letters, 2013, 337, 35-40.	3.2	42
43	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 2020, 26, 5926-5933.	3.2	41
44	Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. British Journal of Cancer, 2020, 122, 1059-1067.	2.9	41
45	UCLA1, a Synthetic Derivative of a gp120 RNA Aptamer, Inhibits Entry of Human Immunodeficiency Virus Type 1 Subtype C. Journal of Virology, 2012, 86, 4989-4999.	1.5	38
46	Melanoma circulating tumor cells: Benefits and challenges required for clinical application. Cancer Letters, 2018, 424, 1-8.	3.2	38
47	Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129736.	1.1	38
48	Structure and Molecular Interactions of a Unique Antitumor Antibody Specific for N-Glycolyl GM3. Journal of Biological Chemistry, 2004, 279, 5597-5603.	1.6	37
49	4E10-Resistant Variants in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Individual with an Anti-Membrane-Proximal External Region-Neutralizing Antibody Response. Journal of Virology, 2008, 82, 2367-2375.	1.5	37
50	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine, 2016, 12, 196-207.	2.7	34
51	A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision. Translational Vision Science and Technology, 2019, 8, 12.	1.1	33
52	Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues. Journal of Molecular Diagnostics, 2018, 20, 240-252.	1.2	32
53	A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells. Molecular Immunology, 2002, 39, 103-112.	1.0	31
54	Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Cells, 2020, 9, 2393.	1.8	31

#	Article	IF	Citations
55	Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy. , 2020, 8, e001620.		30
56	A diagnostic autoantibody signature for primary cutaneous melanoma. Oncotarget, 2018, 9, 30539-30551.	0.8	29
57	A comparative study of extracellular vesicle-associated and cell-free DNA and RNA for HPV detection in oropharyngeal squamous cell carcinoma. Scientific Reports, 2020, 10, 6083.	1.6	28
58	Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring. Frontiers in Oncology, 2013, 3, 54.	1.3	27
59	Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma. JCO Precision Oncology, 2018, 2, 1-12.	1.5	27
60	Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. Virology, 2013, 446, 66-76.	1.1	25
61	Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo. BMC Dermatology, 2016, 16, 6.	2.1	23
62	Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. Oncotarget, 2019, 10, 113-122.	0.8	23
63	Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth. Prostate Cancer and Prostatic Diseases, 2022, 25, 86-92.	2.0	23
64	Future perspectives of uveal melanoma blood based biomarkers. British Journal of Cancer, 2022, 126, 1511-1528.	2.9	22
65	Myokine Expression and Tumor-Suppressive Effect of Serum after 12 wk of Exercise in Prostate Cancer Patients on ADT. Medicine and Science in Sports and Exercise, 2022, 54, 197-205.	0.2	21
66	Tumour- associated autoantibodies as prognostic cancer biomarkers- a review. Autoimmunity Reviews, 2022, 21, 103041.	2.5	21
67	South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on Î±4Î²7 for replication. Retrovirology, 2015, 12, 54.	0.9	19
68	Genomic Analysis of Circulating Tumor DNAÂUsing a Melanoma-Specific UltraSEEK Oncogene Panel. Journal of Molecular Diagnostics, 2019, 21, 418-426.	1.2	18
69	Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. British Journal of Cancer, 2022, 126, 401-408.	2.9	18
70	Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition. Cancers, 2021, 13, 1740.	1.7	17
71	Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles. Cancers, 2019, 11, 157.	1.7	16
72	Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. Scientific Reports, 2020, 10, 18878.	1.6	16

#	Article	IF	Citations
73	The Epigenetic landscape of Circulating tumour cells. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188514.	3.3	16
74	Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virology Journal, 2013, 10, 347.	1.4	14
75	Changes in plasma hydroxyproline and plasma cell-free DNA concentrations after higher- versus lower-intensity eccentric cycling. European Journal of Applied Physiology, 2021, 121, 1087-1097.	1.2	13
76	Incidence and mortality of uveal melanoma in Australia (1982â€“2014). British Journal of Ophthalmology, 2023, 107, 406-411.	2.1	13
77	Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology, 2012, 433, 410-420.	1.1	12
78	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapiesâ€”Beyond BRAF Mutant Detection. Cancers, 2020, 12, 3793.	1.7	12
79	Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study. Frontiers in Oncology, 2020, 10, 1041.	1.3	12
80	Is Tissue Still the Issue? The Promise of Liquid Biopsy in Uveal Melanoma. Biomedicines, 2022, 10, 506.	1.4	12
81	Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer. Translational Lung Cancer Research, 2022, 11, 440-451.	1.3	12
82	Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancerÂtreated with single agent immunotherapy. European Journal of Cancer, 2022, 172, 98-106.	1.3	12
83	Intra- and intertumoral heterogeneity of liver metastases in a patient with uveal melanoma revealed by single-cell RNA sequencing. Journal of Physical Education and Sports Management, 2021, 7, a006111.	0.5	11
84	Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. Cancers, 2019, 11, 920.	1.7	10
85	Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. Cancers, 2020, 12, 3486.	1.7	10
86	Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report. BMC Cancer, 2019, 19, 1109.	1.1	9
87	Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies. Retrovirology, 2009, 6, 113.	0.9	8
88	Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma. Scientific Reports, 2018, 8, 18036.	1.6	8
89	Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients. Cancers, 2021, 13, 6225.	1.7	8
90	Differences in HIV Type 1 Neutralization Breadth in 2 Geographically Distinct Cohorts in Africa. Journal of Infectious Diseases, 2015, 211, 1461-1466.	1.9	7

#	Article	IF	Citations
91	A standardised protocol for the evaluation of small extracellular vesicles in plasma by imaging flow cytometry. Journal of Immunological Methods, 2019, 468, 61-66.	0.6	7
92	Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. Oncotarget, 2020, 11, 4016-4027.	0.8	6
93	SIRT1 activation mediates heat-induced survival of UVB damaged Keratinocytes. BMC Dermatology, 2017, 17, 8.	2.1	5
94	Identification and characterisation of putative drug binding sites in human ATP-binding cassette B5 (ABCB5) transporter. Computational and Structural Biotechnology Journal, 2021, 19, 691-704.	1.9	5
95	Arterial or Venous: Where Are the Circulating Tumor Cells?. EBioMedicine, 2015, 2, 1596-1597.	2.7	4
96	UCLA1 aptamer inhibition of human immunodeficiency virus type 1 subtype C primary isolates in macrophages and selection of resistance. Biochemistry and Biophysics Reports, 2016, 7, 408-414.	0.7	4
97	Investigating primary preservice teachersâ€™ ultraviolet radiation awareness and perceived ability to teach sun safety. Health Promotion Journal of Australia, 2021, 32, 178-184.	0.6	4
98	Erdheimâ€“Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation. BMJ Case Reports, 2017, 2017, bcr-2017-219720.	0.2	4
99	Analysis of Circulating Tumour Cells in Early-Stage Uveal Melanoma: Evaluation of Tumour Marker Expression to Increase Capture. Cancers, 2021, 13, 5990.	1.7	4
100	Low-Pass Whole-Genome Sequencing as a Method of Determining Copy Number Variations in Uveal Melanoma Tissue Samples. Journal of Molecular Diagnostics, 2020, 22, 429-434.	1.2	3
101	Multi-Marker Immunomagnetic Enrichment of Circulating Melanoma Cells. Methods in Molecular Biology, 2021, 2265, 213-222.	0.4	3
102	Circulating Tumor Cells as Biomarkers in Cancer. Biomarkers in Disease, 2015, , 31-51.	0.0	3
103	Assessment of a Size-Based Method for Enriching Circulating Tumour Cells in Colorectal Cancer. Cancers, 2022, 14, 3446.	1.7	3
104	PD-L1 expression on pre-treatment circulating tumour cells, but not serum VEGF, is predictive of response to pembrolizumab in melanoma. Annals of Oncology, 2018, 29, viii24-viii25.	0.6	2
105	Associations of Physical Activity and Exercise with Health-related Outcomes in Patients with Melanoma During and After Treatment: A Systematic Review. Integrative Cancer Therapies, 2021, 20, 153473542110407.	0.8	2
106	Application of Multiplex Ligand-Activated Probe Amplification (MLPA) and Low Pass Whole Genome Sequencing (LP-WGS) to the Classification/Characterisation of Low Grade Glioneuronal Tumours. Pathology Research and Practice, 2021, 229, 153724.	1.0	2
107	Lab-on-chip platform for circulating tumor cells isolation. Proceedings of SPIE, 2015, , .	0.8	1
108	Transcript-Based Detection of Circulating Melanoma Cells. Methods in Molecular Biology, 2021, 2265, 235-245.	0.4	1

#	Article	IF	Citations
109	Entry inhibition of HIV-1 subtype C isolates. , 2007, , 119-131.		1
110	Repurposing nano-enabled polymeric scaffolds for tumor-wound management and 3D tumor engineering. Regenerative Medicine, 2020, 15, 2229-2247.	0.8	1
111	P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization. Retrovirology, 2009, 6, .	0.9	0
112	P09-04. Charge changes in the alpha2-helix in the C3 region of the HIV-1 subtype C envelope mediate neutralization escape. Retrovirology, 2009, 6, .	0.9	0
113	Circulating Tumor Cells as Biomarkers in Cancer. , 2014, , 1-17.		0
114	Editorial: Insights Into Biomarkers, Cytokines, and Chemokines in Skin Cancer. Frontiers in Medicine, 2019, 6, 199.	1.2	0
115	Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients. Methods in Molecular Biology, 2021, 2265, 247-263.	0.4	0
116	Assessment of tissue and blood tumor mutational burden in patients with melanoma using a 523-gene clinical assay.. Journal of Clinical Oncology, 2022, 40, e21570-e21570.	0.8	0
117	Autoantibodies as potential biomarkers of immune-related adverse events in patients with advanced cutaneous melanoma treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2022, 40, 9536-9536.	0.8	0